# Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

> **NCT05127954** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **AbbVie** · enrollment: 1200 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Ubrogepant

## Key facts

- **NCT ID:** NCT05127954
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-01-14
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127954, "Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05127954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*